ROYAL OAK, Mich.--(BUSINESS WIRE)--OncoCell MDx, a privately held immunogenomics company with a patented liquid biopsy platform, today announced it has changed its name to Immunis.AI. The name was chosen to better reflect the power and breadth of application of the company’s novel Intelligentia™ platform, which assesses and stratifies risk of disease on an individualized basis, earlier in the process, at the cellular level. Intelligentia combines the power of the immune defense system, RNAseq technology and machine learning for the development of proprietary disease-specific algorithms to detect and grade disease with a simple blood test. The company will present as Immunis.AI at the 2020 Biotech Showcase, being held January 13-15, 2020 in San Francisco, California.
Date: Tuesday, January 14, 2020
Time: 10:30 AM
Track: Franciscan D (Ballroom Level)
Venue: Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA 94102
“Our name change reflects the expanded potential of the technology as well as a new stage in the company’s growth and development,” said Mark McDonough, President and CEO of Immunis.AI. “Our Intelligentia platform is unique in leveraging the immune system’s surveillance apparatus to overcome the limitations of cfDNA and circulating tumor cells to improve early stage disease detection, at the point of immune-escape, when there is the best opportunity for cure. We’re continuing to develop the platform in multiple cancer types, where there is a significant opportunity to change the diagnostic paradigms, and we’re now also focusing development in other needed disease states. We’re looking forward to sharing details of our expanded platform and focus areas at Biotech Showcase next week.”
Over the past year, Immunis.AI has built out a new leadership team, convening top executives in life sciences with years of experience leading companies towards commercialization and acquisition. In September 2019, the company announced a series B funding of $22.2 million to help advance their novel platform towards commercialization. The company’s novel technologies were created at Harvard University by co-founder, Professor Amin I. Kassis, in 2012. Through 2019, the company advanced its internal discovery studies, intellectual property portfolio, and patient databases. In 2020, the company plans to launch its first noninvasive diagnostic test for early prostate cancer detection, and to further advance development of tests in other diseases.
To schedule a meeting with Mark McDonough during the conference, or for additional details, please contact shannoncaudill@ententeinc.com.
About Immunis.AI
Immunis.AI is a privately held immunogenomics company with a patented liquid biopsy platform that offers unique insights into disease biology, for a truly individualized assessment. Our Intelligentia platform combines the power of the immune defense system, RNAseq technology and machine learning for the development of proprietary disease-specific algorithms. Our approach compares the differential gene expression patterns from two immune cells, using the patient as the control, normalizing and enhancing the signal of the underlying pathology. Intelligentia is a disruptive alternative, leveraging the immune system’s surveillance apparatus to overcome the limitations of cfDNA and CTC’s, enabling us to improve early stage disease detection, at the point of immune-escape, when there is the best opportunity for cure. For more information, please visit: immunis.ai
